-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Xinda Biopharmaceuticals today announced a cooperation agreement with Indonesian biotech company PT Etana Biotechnologies Indonesia (Etana) on Dayo and ® (Beval Pearl Single Anti-Injection), and Thyda Bio granted Etana Daju ® exclusive license in Indonesia for Etana to bring Davao to the local market®.
will receive development and sales milestone payments and a double-digit percentage of net sales.
specific financial terms are not suitable for disclosure.
and ® were approved for listing by the China Drug Administration on June 17, 2020 and authorized their commercial interests in the U.S. and Canada to Coherus BioSciences in January 2020.
the transaction is subject to customary closing conditions.
With regard to daju with ® (beval bead monoantigen injection) with ® is a biologically similar drug for beval bead monoinjeant, also known as recombinant anti-VEGF humanized monoclonal antibody injection.
VEGF is an important factor in angiogenesic process, over-pathological expression in endoblast cells in most human tumors.
anti-VEGF antibody, it can selectively bind VEGF with high affinity, blocking PI3K-Akt/PKB and Ras-Raf-MEK-ER by blocking VEGF from binding to the body on the surface of its vascular endostrote cells The conduction of signaling paths such as K inhibits the growth, proliferation, migration and angiogenesia of endoblast cells, reduces vascular permeability, blocks the blood supply of tumor tissue, inhibits the proliferation and metastasis of tumor cells, and induces tumor apoptosis, thus achieving the therapeutic effect of anti-tumor.
Since its launch, the original drug Beval pearl single anti-injection has been approved worldwide for the treatment of non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, fallopian tube cancer, peritometrial cancer and other solid tumors, its remarkable efficacy and good safety has been generally recognized.
On June 17, 2020, Daju and ® (Beva Pearl Monoantigen Injection) were first approved for the NMPA market for the treatment of advanced non-small cell lung cancer and metastasis colorectal cells, and in December 2020 NMPA was approved for the treatment of adult relapsed glioblastoma.
note: There are deletions in the original text
